Cerus Corporation
Moat Score — Cerus Corporation
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Cerus holds roughly 182 combined U.S. and foreign patents on its INTERCEPT technology (expiring 2025-2042) and is currently the only FDA-approved pathogen-reduction system for platelets in the U.S., a strong regulatory and IP moat in a niche but essential category. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Cerus outsources manufacturing to sole-source partners (Fresenius Kabi, Porex, Piramal) rather than owning production scale itself, and its own disclosures note contribution margins are likely below operating expenses, limiting any cost-based advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Being the sole FDA-approved U.S. platelet pathogen-reduction system gives Cerus real near-term pricing leverage with blood centers, tempered by the reality that most customers are budget-constrained nonprofit/public blood organizations and reimbursement dynamics limit how much of that leverage converts to margin. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Blood-safety technology adoption by one blood center does not make the INTERCEPT system more valuable to other blood centers; there is no network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Once a national blood collection organization like the American Red Cross, EFS, or NHSBT adopts INTERCEPT, switching to an alternative pathogen-reduction system requires new regulatory validation, equipment changeover, and staff retraining, creating high real-world switching costs given the patient-safety stakes involved. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The extremely high regulatory barriers to developing and approving a pathogen-reduction blood product limit the credible competitive set to a handful of global players (Grifols, Octapharma, Terumo BCT, Cerus), giving incumbents like Cerus a meaningful efficient-scale advantage over new entrants. |